Skip to main content
. 2018 Apr 23;7(6):2567–2580. doi: 10.1002/cam4.1487

Figure 6.

Figure 6

Celecoxib administration activates antitumor immunity in Novikoff HCC during epirubicin therapy. Immunohistochemistry analysis. (A) FOXP3, (B) CD68, (C) CD8, and (D) PD‐L1 from tumor tissues after therapy for 7 days. Data were mean ± SD (n.s. = no significance, *< 0.05, **< 0.01). Scale bar = 50 μm.